3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
53
Lymphoma
44
Lymphoma, Large B-Cell, Diffuse
35
Lymphoma, Follicular
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma, Non-Hodgkin
22
Multiple Myeloma
19
Leukemia
17
Burkitt Lymphoma
13
Hodgkin Disease
12
Lymphoma, Mantle-Cell
10
Neoplasms
8
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, Large-Cell, Anaplastic
7
Neoplasms, Plasma Cell
6
Neoplasm Metastasis
6
Lymphoma, T-Cell, Peripheral
6
Recurrence
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pain
3
Lymphoma, B-Cell
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Leukemia, Biphenotypic, Acute
2
Disease
2
Interventions
pembrolizumab
95
Cisplatin
35
Paclitaxel
27
Carboplatin
27
Docetaxel
17
lenvatinib
15
Fluorouracil
14
Saline Solution
13
Capecitabine
12
Pemetrexed
10
Gemcitabine
10
Oxaliplatin
9
Cetuximab
7
Albumin-Bound Paclitaxel
7
olaparib
6
epacadostat
6
Bevacizumab
6
130-nm albumin-bound paclitaxel
6
Leucovorin
5
enzalutamide
4
Etoposide
4
trifluridine tipiracil drug combination
3
regorafenib
3
belzutifan
3
Prednisone
3
Irinotecan
3
Glucose
3
Dexamethasone
3
liposomal doxorubicin
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Prednisone
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT03834519
2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3
Completed
793 enrolled
23 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts